These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 10557874)

  • 21. National health insurance: lessons from the United States experiment.
    Derrick FW; Scott CE
    Health Care Manage Rev; 1995; 20(3):55-63. PubMed ID: 7591752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bundled-rate legislation for Medicare reimbursement for dialysis services: implications for anemia management with ESAs.
    Charytan C
    Clin J Am Soc Nephrol; 2010 Dec; 5(12):2355-62. PubMed ID: 21071515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The success of medicare's end-stage renal-disease program: the case for profits and the private marketplace.
    Lowrie EG; Hampers CL
    N Engl J Med; 1981 Aug; 305(8):434-8. PubMed ID: 7019710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medicare program; end-stage renal disease prospective payment system, quality incentive program, and bad debt reductions for all Medicare providers. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2012 Nov; 77(218):67450-531. PubMed ID: 23139948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Why should your practice perform compliance audits based on the latest OIG Work Plan?
    Hammon M
    J Okla State Med Assoc; 2005 Mar; 98(3):95-7. PubMed ID: 15822723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Legal basis and interpretations of medical necessity.
    Kazon PM
    Clin Lab Manage Rev; 1998; 12(5):375-82; discussion 382-3. PubMed ID: 10185017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tips for challenging an audit based on statistical sampling.
    Shaw PW; Tichner JB
    J Health Law; 1999; 32(4):649-56. PubMed ID: 10662443
    [No Abstract]   [Full Text] [Related]  

  • 28. AHIMA (American Health Information Management Association) census results: focus on compliance.
    Lorence DP
    J AHIMA; 1999 Apr; 70(4):48-52. PubMed ID: 10350973
    [No Abstract]   [Full Text] [Related]  

  • 29. Managing oral phosphate binder medication expenditures within the Medicare bundled end-stage renal disease prospective payment system: economic implications for large U.S. dialysis organizations.
    Park H; Rascati KL; Keith MS
    J Manag Care Spec Pharm; 2015 Jun; 21(6):507-14. PubMed ID: 26011552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A review of Medicaid rate reductions in 2011.
    Schrag WF
    Nephrol News Issues; 2012 Jan; 26(1):11-2. PubMed ID: 22363948
    [No Abstract]   [Full Text] [Related]  

  • 31. Futuristic plans for ESRD--a new bundled payment system.
    Michael M
    Nephrol News Issues; 2005 Sep; 19(10):52, 54. PubMed ID: 16187649
    [No Abstract]   [Full Text] [Related]  

  • 32. Renal Dialysis and its Financing.
    Borelli M; Paul DP; Skiba M
    Hosp Top; 2016; 94(2):33-8. PubMed ID: 27315562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The 2011 ESRD prospective payment system: perspectives from DaVita, a for-profit large dialysis organization.
    Nissenson AR; Mayne TJ; Krishnan M
    Am J Kidney Dis; 2011 Apr; 57(4):550-2. PubMed ID: 21333425
    [No Abstract]   [Full Text] [Related]  

  • 34. Erythropoietin & ESRD payments: a promising policy outcome?
    Roe W
    Nephrol News Issues; 1989 Sep; 3(9):34-5. PubMed ID: 2682270
    [No Abstract]   [Full Text] [Related]  

  • 35. Medicare program; clarification of resumption of entitlement rules for Medicare patients with end-stage renal disease (ESRD)--HCFA. Final rule.
    Fed Regist; 1995 May; 60(88 Pt 1):22533-5. PubMed ID: 10142805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reforming medicare's dialysis payment policies: implications for patients with secondary hyperparathyroidism.
    Gupta C; Chertow GM; Linthicum MT; Van Nuys K; Belozeroff V; Quarles D; Lakdawalla DN
    Health Serv Res; 2014 Dec; 49(6):1925-43. PubMed ID: 25040130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The direction of end-stage renal disease reimbursement in the United States.
    Lockridge RS
    Semin Dial; 2004; 17(2):125-30. PubMed ID: 15043614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The 2011 ESRD prospective payment system: perspectives from a for-profit small- to medium-sized dialysis organization.
    Bhat P; Bhat JG
    Am J Kidney Dis; 2011 Apr; 57(4):556-8. PubMed ID: 21316132
    [No Abstract]   [Full Text] [Related]  

  • 39. The organization of medical care. Lessons from the Medicare end stage renal disease program.
    Levinsky NG
    N Engl J Med; 1993 Nov; 329(19):1395-9. PubMed ID: 8413437
    [No Abstract]   [Full Text] [Related]  

  • 40. Projected impact of the proposed "bundled" ESRD payment system on a small dialysis organization.
    Bhat P; Sokolowski W; Bhat JG
    Nephrol News Issues; 2009 Jun; 23(7):46, 48-52. PubMed ID: 19585810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.